ClaireHenchcliffeMDDPhil(She/Her)

Neurology • Irvine, CA

Movement Disorder

Chair and Stanley van den Noort Professor in Neurology, UC Irvine

Join to view full profile

Dr. Henchcliffe is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Henchcliffe's full profile

Already have an account?

Office
1 Medical Plaza Drive
Irvine, CA 92697
Phone+1 949-824-8600

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Neuromuscular Medicine (Neurology), 2001 - 2003
New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1998 - 2001
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 1998
Columbia University Vagelos College of Physicians and SurgeonsClass of 1997
University of California, BerkeleyPost-Doctoral Fellowship, 1989 - 1992
University of Oxford, Sir William Dunn School of PathologyD.Phil., Molecular/Cell Biology, 1985 - 1988
University of Oxford, Keble CollegeBA, Biochemistry, 1st Class Honors, 1981 - 1985

Certifications & Licensure

CA State Medical License 2020 - 2026
NY State Medical License 1998 - 2021
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Fellow (FAAN) American Academy of Neurology
Fellow (FANA) American Neurological Association
Daisy and Paul Soros Clinical Scholar in Neurology Weill Cornell Medical College, 2006-2012
Member (AOA) Alpha Omega Alpha Honor Medical Society, 1997
Gibbs Prize in Biochemistry University of Oxford, 1985
Open Scholarship University of Oxford UK, 1982-1985
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Join now to see all

Clinical Trials

Psychiatric and Cognitive Manifestations of Parkinson's Disease Start of enrollment: 2006 Jun 01
Completed
Risk Factors for Progressive Supranuclear Palsy (PSP) Start of enrollment: 2006 Aug 01
Completed
Study to Evaluate SYN115 in Parkinson's Disease Start of enrollment: 2008 Apr 01
Completed
Phase 2
Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study) Start of enrollment: 2006 Sep 01
Completed
Effects of Coenzyme Q10 (CoQ) in Parkinson Disease Start of enrollment: 2008 Dec 01
Terminated
Phase 3
Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD) Start of enrollment: 2010 Nov 01
Completed
Phase 2
N-Acetylcysteine for Neuroprotection in Parkinson's Disease Start of enrollment: 2012 Jan 01
Completed
Phase 1, Phase 2
Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy Start of enrollment: 2010 Sep 14
Completed
Phase 1, Phase 2
Fox Investigation for New Discovery of Biomarkers Start of enrollment: 2012 Oct 01
Completed
Natural History Study of Synucleinopathies Start of enrollment: 2011 Jun 01
Recruiting
Continued Access Protocol: ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors Start of enrollment: 2015 Apr 01
Active, not recruiting
Not Applicable
Study of Urate Elevation in Parkinson's Disease, Phase 3 Start of enrollment: 2016 Jun 01
Completed
Phase 3
Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers Start of enrollment: 2012 Feb 28
Completed
Phase 2
Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease Start of enrollment: 2018 Jan 10
Terminated
Phase 2
ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease Start of enrollment: 2018 Feb 09
Active, not recruiting
Not Applicable
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease Start of enrollment: 2018 Sep 28
Recruiting
Not Applicable
Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls Start of enrollment: 2018 Aug 14
Active, not recruiting
Phase 1, Phase 2
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL) Start of enrollment: 2020 Jan 03
Recruiting
Phase 1, Phase 2
Environmental Epidemiology of Essential Tremor Start of enrollment: 2020 Jul 02
Completed
Join now to see all

Publications & Presentations

PubMed

49 citations
NEURON DEATH IN THE SUBSTANTIA NIGRA OF WEAVER MOUSE OCCURS LATE IN DEVELOPMENT AND IS NOT APOPTOTIC
Tinmarlar F. Oo, Richard Blazeski, Susan M. W. Harrison, Claire Henchcliffe, Carol A. Mason
The Journal of Neuroscience. 1996-10-01
173 citations
The future of stem cell therapies for Parkinson disease
Malin Parmar, Shane Grealish, Claire Henchcliffe
Nature Reviews. Neuroscience. 2020-01-06
37 citations
Cell type specific trans-acting factors are involved in alternative splicing of human fibronectin pre-mRNA.
M V Barone, Claire Henchcliffe, F.E. Baralle, Giovanni Paolella
The EMBO Journal. 1989-04-01

Press Mentions

BlueRock Therapeutics to Incorporate Wearable and Invisible Contactless Digital Health Technologies from Rune Labs and Emerald Innovations in Parkinson’s Disease Clinical TrialMarch 14th, 2023
BlueRock Therapeutics Announces Completion of Enrollment of Phase 1 Trial in Patients with Parkinson's DiseaseMay 31st, 2022
Scientists Reverse Motor Symptoms in Parkinson's Disease ModelAugust 6th, 2020
Join now to see all